Keybank National Association OH Has $4.88 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Keybank National Association OH boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,118 shares of the pharmaceutical company’s stock after acquiring an additional 147 shares during the quarter. Keybank National Association OH’s holdings in Vertex Pharmaceuticals were worth $4,880,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Torray Investment Partners LLC lifted its holdings in shares of Vertex Pharmaceuticals by 1.6% during the 4th quarter. Torray Investment Partners LLC now owns 16,008 shares of the pharmaceutical company’s stock valued at $6,446,000 after buying an additional 257 shares during the last quarter. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Vertex Pharmaceuticals by 40.0% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,781 shares of the pharmaceutical company’s stock valued at $712,000 after buying an additional 509 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,663,849 shares of the pharmaceutical company’s stock valued at $670,032,000 after buying an additional 37,502 shares during the last quarter. Schechter Investment Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 23.9% during the 4th quarter. Schechter Investment Advisors LLC now owns 2,920 shares of the pharmaceutical company’s stock valued at $1,176,000 after buying an additional 563 shares during the last quarter. Finally, Grandfield & Dodd LLC lifted its holdings in shares of Vertex Pharmaceuticals by 19.9% during the 4th quarter. Grandfield & Dodd LLC now owns 16,964 shares of the pharmaceutical company’s stock valued at $6,831,000 after buying an additional 2,820 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Ourania Tatsis sold 530 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the transaction, the executive vice president now owns 58,539 shares of the company’s stock, valued at $27,825,928.26. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 1,084 shares of company stock worth $505,512. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $491.64 on Thursday. The company has a market cap of $126.25 billion, a P/E ratio of -223.47, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The business’s 50 day moving average is $445.18 and its two-hundred day moving average is $461.33.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRTX. Piper Sandler reduced their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a report on Monday, January 27th. HC Wainwright reiterated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a report on Thursday, February 20th. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 11th. Finally, Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price for the company. in a report on Thursday, January 30th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.